Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression

BACKGROUND: Tumor endothelial marker 1 (TEM1) is a protein expressed in the tumor-associated endothelium and/or stroma of various types of cancer. We previously demonstrated that immunization with a plasmid-DNA vaccine targeting TEM1 reduced tumor progression in three murine cancer models. Radiation...

Descripción completa

Detalles Bibliográficos
Autores principales: Pierini, Stefano, Mishra, Abhishek, Perales-Linares, Renzo, Uribe-Herranz, Mireia, Beghi, Silvia, Giglio, Andrea, Pustylnikov, Sergei, Costabile, Francesca, Rafail, Stavros, Amici, Augusto, Facciponte, John G, Koumenis, Costantinos, Facciabene, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875275/
https://www.ncbi.nlm.nih.gov/pubmed/33563772
http://dx.doi.org/10.1136/jitc-2020-001636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875275/
https://www.ncbi.nlm.nih.gov/pubmed/33563772
http://dx.doi.org/10.1136/jitc-2020-001636

Ejemplares similares